Australia's most trusted
source of pharma news
Saturday, 21 December 2024
Posted 18 December 2024 PM
Novo Nordisk has informed the TGA that supply of its diabetes treatment Ozempic will continue to remain "limited" throughout 2025 as it continues to grapple with increased consumer demand worldwide due to off-label prescribing for obesity.
The latest update means that the shortage of the semaglutide-containing medicine, which started on 15 April 2022 will push out to almost four years.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.